CD19 and acute lymphoblastic leukemia: On the other hand, the access to CD19-targeted CAR-T therapy for adult r/r B-ALL patients was not granted until recently, when in October 2021 the FDA approved brexucabtagene autoleucel (Tecartus) for such indication.